Alecensaro for Non-Small Cell Lung Cancer (first line) – Details


( Last Updated : August 13, 2018)
Generic Name:
Alectinib
Project Status:
Complete
Therapeutic Area:
Locally advanced or metastatic ALK+ NSCLC (first line)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Alecensaro
Project Line:
Reimbursement Review
Project Number:
PC0125-000
NOC Status at Filing:
Pre NOC
NOC Date:

Details


Strength:
150 mg
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (first line)
Funding Request:
For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.